# MS-Therapie: Rituximab ist Ocrelizumab nicht unterlegen

Page: https://stenobird.com/podcast/ne-dosis-wissen-der-medizin-podcast-f-r-menschen-im-gesundheitswesen-5831376/ms-therapie-rituximab-ist-ocrelizumab-nicht-unterlegen
Text version: https://stenobird.com/podcast/ne-dosis-wissen-der-medizin-podcast-f-r-menschen-im-gesundheitswesen-5831376/ms-therapie-rituximab-ist-ocrelizumab-nicht-unterlegen.md
Podcast: ['ne Dosis Wissen | Der Medizin-Podcast für Menschen im Gesundheitswesen](https://stenobird.com/podcast/ne-dosis-wissen-der-medizin-podcast-f-r-menschen-im-gesundheitswesen-5831376)
Published: 2026-07-20T03:00:00+00:00
Episode link: https://nedosiswissen.podigee.io/1114-ms-therapie-rituximab-ist-ocrelizumab-nicht-unterlegen
Audio file: https://audio.podigee-cdn.net/2549816-m-130b29459879c50ca02f11fca55a7a5f.mp3?source=feed
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/ne-dosis-wissen-der-medizin-podcast-f-r-menschen-im-gesundheitswesen-5831376/episodes/ms-therapie-rituximab-ist-ocrelizumab-nicht-unterlegen
Duration seconds: 388

## Resource

Ob man das günstigere Rituximab bei Multipler Sklerose Ocrelizumab vorziehen sollte, erklärt Dennis Ballwieser.

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/ne-dosis-wissen-der-medizin-podcast-f-r-menschen-im-gesundheitswesen-5831376/episodes/ms-therapie-rituximab-ist-ocrelizumab-nicht-unterlegen/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/ne-dosis-wissen-der-medizin-podcast-f-r-menschen-im-gesundheitswesen-5831376/ms-therapie-rituximab-ist-ocrelizumab-nicht-unterlegen.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.